Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | CTRC | Q99895 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9611221 | 0.80 | KDM4E (0.41) | MAPTTDP1MGLLLMNAPOLB | |
| SCHEMBL22295922 | 0.76 | ACHE (0.38) | ADRB1MAPTTDP1ACHENPSR1 | |
| SCHEMBL7375301 | 0.72 | ADRB1 (0.36) | ADRB1F2ELANECTSGCMA1 | |
| SCHEMBL5854414 | 0.64 | ADRB1 (0.54) | ADRB1F2ELANECTSGCMA1 | |
| SCHEMBL10361315 | 0.64 | F2 (0.35) | ADRB1F2ELANECTSGCMA1 | |
| SCHEMBL28353519 | 0.64 | F2 (0.35) | ADRB1F2ELANECTSGCMA1 | |
| SCHEMBL1105689 | 0.64 | F2 (0.39) | ADRB1F2ELANECTSGCMA1 | |
| SCHEMBL12230241 | 0.63 | ACHE (0.50) | ADRB1F2ELANECTSGCMA1 | |
| SCHEMBL28273973 | 0.63 | ACHE (0.50) | ADRB1F2ELANECTSGCMA1 | |
| P-Xylene SCHEMBL9420946 | 0.63 | ACHE (0.89) | TDP1ACHELMNAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |
| US-9278971-B2 | Substituted acetylenic pyrazolo[1,5-a]pyrimidines as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2024366-B1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2015-09-16 | — | — | EP | disclosed |
| US-9090561-B2 | Acetylenic heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9029533-B2 | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | ARIAD PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20140288082-A1 | Bicyclic Heteroaryl Compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2014-09-25 | — | — | US | disclosed |
| US-8778942-B2 | Substituted acetylenic imidazo[1,2-A]pyrazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2743266-A2 | PROTEIN KINASE INHIBITORS (VARIANTS), USE THEREOF IN TREATING ONCOLOGICAL DISEASES AND A PHARMACEUTICAL COMPOSITION BASED THEREON | Obshchestvo S Ogranichennoy Otvetstvennostyou "Fusion Pharma" (RU) | 2014-06-18 | — | — | EP | disclosed |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130196979-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013101281-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | ARIAD PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-8470851-B2 | Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8461167-B2 | Acetylenic heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8071609-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | CYP2F1, CYP2J2, ALOX5 | ADRB1 2606/4885F2 171/4885ELANE 901/4885 |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | PARK7, SNCA, HTT | ADRB1 667/4885F2 2722/4885ELANE 2167/4885 |
| US-20130196979-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ADRB1 1742/4885F2 124/4885ELANE 1112/4885 |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | BRAF, RAF1, NRAS | ADRB1 3622/4885F2 3771/4885ELANE 2050/4885 |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, MAPT, SNCA | ADRB1 2272/4885F2 4651/4885ELANE 2278/4885 |
| US-20140288082-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ADRB1 1742/4885F2 124/4885ELANE 1112/4885 |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ADRB1 1742/4885F2 124/4885ELANE 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.